These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 18675868)

  • 41. Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis.
    Santos WR; de Lima VM; de Souza EP; Bernardo RR; Palatnik M; Palatnik de Sousa CB
    Vaccine; 2002 Nov; 21(1-2):30-43. PubMed ID: 12443660
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Immunoprophylactic Potential of a New Recombinant
    Pessoa-E-Silva R; Trajano-Silva LAM; Vaitkevicius-Antão V; Dos Santos WJT; Magalhães FB; Moura DMN; Nakasone EKN; de Lorena VMB; de Paiva-Cavalcanti M
    Front Immunol; 2020; 11():605044. PubMed ID: 33488607
    [TBL] [Abstract][Full Text] [Related]  

  • 43. One-year timeline kinetics of cytokine-mediated cellular immunity in dogs vaccinated against visceral leishmaniasis.
    Costa-Pereira C; Moreira ML; Soares RP; Marteleto BH; Ribeiro VM; França-Dias MH; Cardoso LM; Viana KF; Giunchetti RC; Martins-Filho OA; Araújo MS
    BMC Vet Res; 2015 Apr; 11():92. PubMed ID: 25880646
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Temporal IgG subclasses response in dogs following vaccination against Leishmania with Leishmune®.
    Marcondes M; Ikeda FA; Vieira RF; Day MJ; Lima VM; Rossi CN; Perri SH; Biondo AW
    Vet Parasitol; 2011 Sep; 181(2-4):153-9. PubMed ID: 21530083
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccines for visceral leishmaniasis: A review.
    Jain K; Jain NK
    J Immunol Methods; 2015 Jul; 422():1-12. PubMed ID: 25858230
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Leishmune vaccine: the newest tool for prevention and control of canine visceral leishmaniosis and its potential as a transmission-blocking vaccine.
    Dantas-Torres F
    Vet Parasitol; 2006 Oct; 141(1-2):1-8. PubMed ID: 16750885
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Recombinant Forms of Leishmania amazonensis Excreted/Secreted Promastigote Surface Antigen (PSA) Induce Protective Immune Responses in Dogs.
    Petitdidier E; Pagniez J; Papierok G; Vincendeau P; Lemesre JL; Bras-Gonçalves R
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004614. PubMed ID: 27223609
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis.
    Gupta R; Kumar V; Kushawaha PK; Tripathi CP; Joshi S; Sahasrabuddhe AA; Mitra K; Sundar S; Siddiqi MI; Dube A
    PLoS One; 2014; 9(1):e86073. PubMed ID: 24475071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Protective immunity against challenge with Leishmania (Leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein.
    Fernandes AP; Costa MM; Coelho EA; Michalick MS; de Freitas E; Melo MN; Luiz Tafuri W; Resende Dde M; Hermont V; Abrantes Cde F; Gazzinelli RT
    Vaccine; 2008 Oct; 26(46):5888-95. PubMed ID: 18786587
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Evaluation of a prototype flow cytometry test for serodiagnosis of canine visceral leishmaniasis.
    Ker HG; Coura-Vital W; Aguiar-Soares RD; Roatt BM; das Dores Moreira N; Carneiro CM; Machado EM; Teixeira-Carvalho A; Martins-Filho OA; Giunchetti RC; Araújo MS; Coelho EA; da Silveira-Lemos D; Reis AB
    Clin Vaccine Immunol; 2013 Dec; 20(12):1792-8. PubMed ID: 24108778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Canine visceral leishmaniasis biomarkers and their employment in vaccines.
    Giunchetti RC; Silveira P; Resende LA; Leite JC; Melo-Júnior OAO; Rodrigues-Alves ML; Costa LM; Lair DF; Chaves VR; Soares IDS; de Mendonça LZ; Lanna MF; Ribeiro HS; Maia-Gonçalves AA; Santos TAP; Roatt BM; Aguiar-Soares RDO; Vitoriano-Souza J; das Dores Moreira N; Mathias FAS; Cardoso JMO; Coura-Vital W; Galdino AS; Viana KF; Martins-Filho OA; Silveira-Lemos DD; Dutra WO; Reis AB
    Vet Parasitol; 2019 Jul; 271():87-97. PubMed ID: 31303211
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunogenicity of a killed Leishmania vaccine with saponin adjuvant in dogs.
    Giunchetti RC; Corrêa-Oliveira R; Martins-Filho OA; Teixeira-Carvalho A; Roatt BM; de Oliveira Aguiar-Soares RD; de Souza JV; das Dores Moreira N; Malaquias LC; Mota e Castro LL; de Lana M; Reis AB
    Vaccine; 2007 Nov; 25(44):7674-86. PubMed ID: 17913311
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Enhanced efficacy and immunogenicity of 78kDa antigen formulated in various adjuvants against murine visceral leishmaniasis.
    Nagill R; Kaur S
    Vaccine; 2010 May; 28(23):4002-12. PubMed ID: 20093205
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis.
    Carson C; Antoniou M; Ruiz-Argüello MB; Alcami A; Christodoulou V; Messaritakis I; Blackwell JM; Courtenay O
    Vaccine; 2009 Feb; 27(7):1080-6. PubMed ID: 19095029
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Making an anti-amastigote vaccine for visceral leishmaniasis: rational, update and perspectives.
    Fernandes AP; Coelho EA; Machado-Coelho GL; Grimaldi G; Gazzinelli RT
    Curr Opin Microbiol; 2012 Aug; 15(4):476-85. PubMed ID: 22698479
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antigenicity and protective efficacy of a Leishmania amastigote-specific protein, member of the super-oxygenase family, against visceral leishmaniasis.
    Martins VT; Chávez-Fumagalli MA; Costa LE; Canavaci AM; Martins AM; Lage PS; Lage DP; Duarte MC; Valadares DG; Magalhães RD; Ribeiro TG; Nagem RA; Darocha WD; Régis WC; Soto M; Coelho EA; Fernandes AP; Tavares CA
    PLoS Negl Trop Dis; 2013; 7(3):e2148. PubMed ID: 23573301
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Delay in the Licensing of Protozoal Vaccines: A Comparative History.
    Palatnik-de-Sousa CB; Nico D
    Front Immunol; 2020; 11():204. PubMed ID: 32210953
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Kinetics of cell migration to the dermis and hypodermis in dogs vaccinated with antigenic compounds of Leishmania braziliensis plus saponin.
    Vitoriano-Souza J; Reis AB; Moreira ND; Giunchetti RC; Correa-Oliveira R; Carneiro CM
    Vaccine; 2008 Jul; 26(31):3922-31. PubMed ID: 18555567
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunodiagnosis of human and canine visceral leishmaniasis using recombinant Leishmania infantum Prohibitin protein and a synthetic peptide containing its conformational B-cell epitope.
    Rodrigues MR; Santos LMO; Miyazaki CK; Martins VT; Ludolf FR; Kursancew AC; Ramos FF; Dias DS; Oliveira JS; Vieira PMA; Roatt BM; Machado de Ávila RA; Gonçalves DU; Menezes-Souza D; Coelho EAF; Duarte MC
    J Immunol Methods; 2019 Nov; 474():112641. PubMed ID: 31400411
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Studies on cocktails of 31-kDa, 36-kDa and 51-kDa antigens of Leishmania donovani along with saponin against murine visceral leishmaniasis.
    Kaur H; Thakur A; Kaur S
    Parasite Immunol; 2015 Apr; 37(4):192-203. PubMed ID: 25615543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.